Literature DB >> 9880532

The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase.

E G Argyris1, J M Vanderkooi, P S Venkateswaran, B K Kay, Y Paterson.   

Abstract

We have shown that heme and zinc protoporphyrin inhibit both human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) reverse transcriptases (RTs) and, in combination with other nucleoside and non-nucleoside inhibitors, exert an additive effect on HIV-1 RT inhibition. Screening of a phage peptide library against heme resulted in the isolation of a peptide with sequence similarity to sequence 398-407 from the connection subdomain of both HIV-1 and HIV-2 RTs, suggesting that this highly conserved region of HIV RTs corresponds to the binding site for metalloporphyrins and a new site for inhibition of enzyme activity. Inclusion of a synthetic peptide corresponding to the exact sequence 398-407 of HIV-1 RT in RT inhibition assays had a protective effect on metalloporphyrin inhibition, as it was able to reverse the inhibitory effect of both metalloporphyrins on HIV-1 RT activity. Furthermore, intrinsic fluorescence assays indicated that these metalloporphyrins bind to synthetic peptide 398-407 as well as to intact dimeric HIV-1 RT. The identification of this novel inhibition site will help to expand our understanding of the mode of action of metalloporphyrins in RT inhibition and will assist in the design and development of more potent metalloporphyrin RT inhibitors for the management of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880532     DOI: 10.1074/jbc.274.3.1549

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.

Authors:  Maxime Lecerf; Tobias Scheel; Anastas D Pashov; Annaelle Jarossay; Delphine Ohayon; Cyril Planchais; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

2.  Inactivation of human immunodeficiency virus type 1 by porphyrins.

Authors:  Andrei N Vzorov; Dabney W Dixon; Jenna S Trommel; Luigi G Marzilli; Richard W Compans
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.

Authors:  Zhaowen Zhu; M Meleah Mathahs; Warren N Schmidt
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

4.  A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Authors:  Jordan D Dimitrov; Cyril Planchais; Tobias Scheel; Delphine Ohayon; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

5.  Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds.

Authors:  Li Lin; Jianming Hu
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

6.  Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition.

Authors:  Ping La; Amal P Fernando; Zhi Wang; Ameen Salahudeen; Guang Yang; Qing Lin; Clyde J Wright; Phyllis A Dennery
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

7.  Changes in simian immunodeficiency virus reverse transcriptase alleles that appear during infection of macaques enhance infectivity and replication in CD4+ T cells.

Authors:  Tasha Biesinger; Monica T Yu Kimata; Jason T Kimata
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

8.  Heme and HO-1 Inhibition of HCV, HBV, and HIV.

Authors:  Warren N Schmidt; M Meleah Mathahs; Zhaowen Zhu
Journal:  Front Pharmacol       Date:  2012-10-04       Impact factor: 5.810

Review 9.  The Application of Porphyrins and Their Analogues for Inactivation of Viruses.

Authors:  Natalya Sh Lebedeva; Yury A Gubarev; Mikhail O Koifman; Oskar I Koifman
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.